

Data Sharing Statement

Pontecorvo. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease. *JAMA Neurol.* Published October 17, 2022.
doi:10.1001/jamaneurol.2022.3392

Data

Data available: Yes

Data types: Other (please specify)

Additional Information: All of the individual participant data collected during the trial, after anonymization with the exception of pharmacokinetic or genetic data.

How to access data: Proposals should be submitted at www.vivli.org data requestors will need to sign a data sharing agreement. Data for each proposal are available in a controlled access environment.

When available: beginning date: 01-31-2024

Supporting Documents

Document types: Other (please specify)

Additional Information: Study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms

How to access documents: Proposals should be submitted at www.vivli.org data requestors will need to sign a data sharing agreement. Data for each proposal are available in a controlled access environment.

When available: beginning date: 01-31-2024

Additional Information

Who can access the data: Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose.

Types of analyses: To achieve aims in the approved proposal

Mechanisms of data availability: Proposals should be submitted at www.vivli.org data requestors will need to sign a data sharing agreement. Data for each proposal are available in a controlled access environment.

Any additional restrictions: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. The data are available indefinitely.